Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit
From these real-world data, patients with cardiorenal and metabolic diseases emerge as a fragile population, with multimorbidity, and a substantial risk of hospitalizations and death, confirming as chronicity represent a priority issue for health systems.
Authors
- Cataldo Procacci (ORCID: https://orcid.org/0000-0001-9505-4340)
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- Marco Gnesi (ORCID: https://orcid.org/0000-0001-6022-6325)
- V. Mongelli (ORCID: https://orcid.org/0000-0001-6022-6325)
- Melania Leogrande (ORCID: https://orcid.org/0009-0004-2092-4638)
- Valentina Perrone
- Silvia Migliaccio (ORCID: https://orcid.org/0000-0002-4563-6630)
- Felice Renato Colanero
- Laura Bonfanti
Institutions
- Azienda Sanitaria Locale di Asti (IT)
- AstraZeneca (Singapore) (SG)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- British American Tobacco (Germany) (DE)
- AstraZeneca (Italy) (IT)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1080/14737167.2025.2504944
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00